Gelatinase A/MMP-2 serum levels and neoplastic progression in breast cancer patients

A. Leone, M. Correale, C. D. Dragone, A. Paradiso, M. De Lena, W. G. Stetler-Stevenson, L. A. Liotta, L. Masiero, S. Garbisa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The metastatic potential of cancer cells has been associated to their ability to elaborate and secrete basement membrane degradative enzymes. In this process a major role appears to be played by a protease known as gelatinase A (72 kDa type IV collagenase, MMP-2). In an effort to assess the significance of these findings to breast cancer progression, we have evaluated the gelatinase A/MMP-2 serum levels in a cohort of 80 breast cancer patients, 27 subjects affected by benign breast disease and 27 healthy controls. Although differences between the three groups were observed, with the highest values monitored in benign breast disease, they were not statistically significant. On the contrary, within the breast cancer cohort, the patients presenting clinical evidence of distant metastases (M+, n=40) had statistically elevated enzyme serum levels (p

Original languageEnglish
Pages (from-to)551-554
Number of pages4
JournalInternational Journal of Oncology
Volume4
Issue number3
Publication statusPublished - 1994

Fingerprint

Matrix Metalloproteinase 2
Matrix Metalloproteinases
Breast Diseases
Breast Neoplasms
Serum
Matrix Metalloproteinase 8
Enzymes
Basement Membrane
Peptide Hydrolases
Neoplasm Metastasis
Neoplasms

Keywords

  • breast cancer
  • gelatinase A
  • metastases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Leone, A., Correale, M., Dragone, C. D., Paradiso, A., De Lena, M., Stetler-Stevenson, W. G., ... Garbisa, S. (1994). Gelatinase A/MMP-2 serum levels and neoplastic progression in breast cancer patients. International Journal of Oncology, 4(3), 551-554.

Gelatinase A/MMP-2 serum levels and neoplastic progression in breast cancer patients. / Leone, A.; Correale, M.; Dragone, C. D.; Paradiso, A.; De Lena, M.; Stetler-Stevenson, W. G.; Liotta, L. A.; Masiero, L.; Garbisa, S.

In: International Journal of Oncology, Vol. 4, No. 3, 1994, p. 551-554.

Research output: Contribution to journalArticle

Leone, A, Correale, M, Dragone, CD, Paradiso, A, De Lena, M, Stetler-Stevenson, WG, Liotta, LA, Masiero, L & Garbisa, S 1994, 'Gelatinase A/MMP-2 serum levels and neoplastic progression in breast cancer patients', International Journal of Oncology, vol. 4, no. 3, pp. 551-554.
Leone A, Correale M, Dragone CD, Paradiso A, De Lena M, Stetler-Stevenson WG et al. Gelatinase A/MMP-2 serum levels and neoplastic progression in breast cancer patients. International Journal of Oncology. 1994;4(3):551-554.
Leone, A. ; Correale, M. ; Dragone, C. D. ; Paradiso, A. ; De Lena, M. ; Stetler-Stevenson, W. G. ; Liotta, L. A. ; Masiero, L. ; Garbisa, S. / Gelatinase A/MMP-2 serum levels and neoplastic progression in breast cancer patients. In: International Journal of Oncology. 1994 ; Vol. 4, No. 3. pp. 551-554.
@article{589968dc30584afb8e99b0cfdef79553,
title = "Gelatinase A/MMP-2 serum levels and neoplastic progression in breast cancer patients",
abstract = "The metastatic potential of cancer cells has been associated to their ability to elaborate and secrete basement membrane degradative enzymes. In this process a major role appears to be played by a protease known as gelatinase A (72 kDa type IV collagenase, MMP-2). In an effort to assess the significance of these findings to breast cancer progression, we have evaluated the gelatinase A/MMP-2 serum levels in a cohort of 80 breast cancer patients, 27 subjects affected by benign breast disease and 27 healthy controls. Although differences between the three groups were observed, with the highest values monitored in benign breast disease, they were not statistically significant. On the contrary, within the breast cancer cohort, the patients presenting clinical evidence of distant metastases (M+, n=40) had statistically elevated enzyme serum levels (p",
keywords = "breast cancer, gelatinase A, metastases",
author = "A. Leone and M. Correale and Dragone, {C. D.} and A. Paradiso and {De Lena}, M. and Stetler-Stevenson, {W. G.} and Liotta, {L. A.} and L. Masiero and S. Garbisa",
year = "1994",
language = "English",
volume = "4",
pages = "551--554",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Gelatinase A/MMP-2 serum levels and neoplastic progression in breast cancer patients

AU - Leone, A.

AU - Correale, M.

AU - Dragone, C. D.

AU - Paradiso, A.

AU - De Lena, M.

AU - Stetler-Stevenson, W. G.

AU - Liotta, L. A.

AU - Masiero, L.

AU - Garbisa, S.

PY - 1994

Y1 - 1994

N2 - The metastatic potential of cancer cells has been associated to their ability to elaborate and secrete basement membrane degradative enzymes. In this process a major role appears to be played by a protease known as gelatinase A (72 kDa type IV collagenase, MMP-2). In an effort to assess the significance of these findings to breast cancer progression, we have evaluated the gelatinase A/MMP-2 serum levels in a cohort of 80 breast cancer patients, 27 subjects affected by benign breast disease and 27 healthy controls. Although differences between the three groups were observed, with the highest values monitored in benign breast disease, they were not statistically significant. On the contrary, within the breast cancer cohort, the patients presenting clinical evidence of distant metastases (M+, n=40) had statistically elevated enzyme serum levels (p

AB - The metastatic potential of cancer cells has been associated to their ability to elaborate and secrete basement membrane degradative enzymes. In this process a major role appears to be played by a protease known as gelatinase A (72 kDa type IV collagenase, MMP-2). In an effort to assess the significance of these findings to breast cancer progression, we have evaluated the gelatinase A/MMP-2 serum levels in a cohort of 80 breast cancer patients, 27 subjects affected by benign breast disease and 27 healthy controls. Although differences between the three groups were observed, with the highest values monitored in benign breast disease, they were not statistically significant. On the contrary, within the breast cancer cohort, the patients presenting clinical evidence of distant metastases (M+, n=40) had statistically elevated enzyme serum levels (p

KW - breast cancer

KW - gelatinase A

KW - metastases

UR - http://www.scopus.com/inward/record.url?scp=0028263238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028263238&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 551

EP - 554

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -